Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Risk factors for asthma exacerbations during pregnancy: a systematic review and meta-analysis

Annelies L. Robijn, Marleen P. Bokern, Megan E. Jensen, Daniel Barker, Katherine J. Baines, Vanessa E. Murphy
European Respiratory Review 2022 31: 220039; DOI: 10.1183/16000617.0039-2022
Annelies L. Robijn
1School of Medicine and Public Health, College of Health, Medicine and Wellbeing, Priority Research Centre for Healthy Lungs, University of Newcastle, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marleen P. Bokern
2Dept of Pharmaco-Therapy, Epidemiology and Economics, University of Groningen, Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Megan E. Jensen
1School of Medicine and Public Health, College of Health, Medicine and Wellbeing, Priority Research Centre for Healthy Lungs, University of Newcastle, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Barker
3School of Medicine and Public Health, University of Newcastle, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katherine J. Baines
1School of Medicine and Public Health, College of Health, Medicine and Wellbeing, Priority Research Centre for Healthy Lungs, University of Newcastle, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vanessa E. Murphy
1School of Medicine and Public Health, College of Health, Medicine and Wellbeing, Priority Research Centre for Healthy Lungs, University of Newcastle, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vanessa E. Murphy
  • For correspondence: vanessa.murphy@newcastle.edu.au
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background Conflicting literature exists regarding the risk factors for exacerbations among pregnant women with asthma. This systematic review and meta-analysis aimed to determine risk factors for asthma exacerbations during pregnancy.

Methods Electronic databases were searched for the following terms: (asthma or wheeze) and (pregnan* or perinat* or obstet*) and (exacerb* or flare up or morbidit* or attack*).

All studies published between 2000 and 24 August 2021 were considered for inclusion if they reported at least one potential risk factor of asthma exacerbations in pregnant women with asthma. Of the 3337 references considered, 35 publications involving 429 583 pregnant women with asthma were included. Meta-analyses were conducted to determine mean difference in risk factor between exacerbation groups, or the relative risks of exacerbation with certain risk factors. Good study quality was found through the Newcastle-Ottawa Scale (median score 8, interquartile range 7–9).

Results Increased maternal age (mean difference 0.62, 95% CI 0.11–1.13), obesity (relative risk 1.25, 95% CI 1.15–1.37), smoking (relative risk 1.35, 95% CI 1.04–1.75), black ethnicity (relative risk 1.62, 95% CI 1.52–1.73), multiparity (relative risk 1.31, 95% CI 1.01–1.68), depression/anxiety (relative risk 1.42, 95% CI 1.27–1.59), moderate–severe asthma (relative risk 3.44, 95% CI 2.03–5.83, versus mild) and severe asthma (relative risk 2.70, 95% CI 1.85–3.95, versus mild–moderate) were associated with an increased risk of asthma exacerbations during pregnancy.

Conclusions Future interventions aimed at reducing exacerbations in pregnancy could address the modifiable factors, such as smoking and depression/anxiety, and introduce more regular monitoring for those with nonmodifiable risk factors such as obesity and more severe asthma.

Abstract

Increased maternal age, obesity, smoking, higher parity and asthma severity are associated with the risk of maternal asthma exacerbations. Future studies need to investigate a “treatable traits” approach to the management of asthma during pregnancy. https://bit.ly/37TuL6A

Introduction

Asthma is the most common medical condition in pregnancy, affecting between 8% and 12% of pregnant women worldwide. Changes in asthma symptoms vary between women and are unpredictable [1–3]. Up to 45% of pregnant women with asthma have an asthma exacerbation requiring medical intervention during pregnancy [4–6]. Both uncontrolled asthma and asthma exacerbations have been associated with increased risk of several adverse perinatal outcomes [7–9]. Furthermore, exacerbations have been associated with poor offspring respiratory health, including asthma [8, 10, 11].

Several studies identified patient-related risk factors for asthma exacerbations during pregnancy, including maternal age [8, 12], smoking [7, 8, 13, 14] and obesity [14–16]. Other studies identified disease-related factors such as increasing asthma severity [4, 5, 14, 17, 18] and lung function [5]. However, risks vary between studies, some studies report no associations, and no previous synthesis of this literature has been conducted.

Given the association between asthma exacerbations in pregnancy and adverse perinatal and infant health outcomes, it is important to identify risk factors that may be modifiable, allowing early identification and additional monitoring of women. The aim of this systematic review and meta-analysis is to synthesise recent literature to determine risk factors for asthma exacerbations during pregnancy and to quantify associations between risk factors and exacerbations.

Methods

The review protocol was registered with the International Prospective Register Of Systematic Reviews (registration number CRD42020196190). The study was reported following the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analysis [19] and the Meta-Analysis of Observational Studies in Epidemiology guidelines [20].

Information sources and search strategy

The search was conducted in electronic MEDLINE, Embase, Cumulative Index to Nursing and Allied Health and Cochrane Clinical Trials Register databases. The search terms (asthma or wheeze) and (pregnan* or perinat* or obstet*) and (exacerb* or flare up or morbidit* or attack*) were used to identify all potential studies for inclusion. The search was limited to studies conducted from 2000 to 24 August 2021 and available as an English-language publication.

Study selection

Using Covidence systematic review software (www.covidence.org), two independent reviewers screened the abstracts of all identified studies and assessed the full texts of potential articles. Disagreements at either stage of study selection were resolved by consensus or referral to a third reviewer. Studies rejected at each stage of the review were recorded, along with the reasons for rejection at the full-text screening stage.

Eligibility

Prospective or retrospective cohort studies, case–control studies and randomised controlled trials (RCTs) were included. We included studies that contained data from pregnant women with physician-diagnosed asthma (whether confirmed or subject self-report) or database-coded asthma diagnosis.

Exposures included patient characteristics that may be risk factors/predictors of exacerbation, including demographic characteristics, asthma characteristics, other health-related characteristics or pregnancy characteristics.

The outcome was asthma exacerbations requiring medical intervention such as hospitalisations, emergency department visits, unscheduled physician visits or oral corticosteroid (OCS) courses for asthma during pregnancy.

Data extraction

Data from included studies was extracted and recorded in a standardised form including study population details, exacerbation definition and years and country of data collection. Data extraction was performed by one reviewer and checked by a second, with discrepancies resolved by discussion reaching consensus.

Risk of bias assessment

Included studies were independently assessed by two reviewers, using the Newcastle–Ottawa Scale [21] for observational studies and the Cochrane Risk of Bias tool [22] for RCTs. Quality scores were recorded with extracted data. GRADE (Grading of Recommendations, Assessment, Development and Evaluations) was used to determine certainty of the meta-analysis results [23].

Data synthesis and analysis

Narrative synthesis of the findings is structured around subject characteristics and distribution of potential predictors. Meta-analyses were conducted for risk factors reported by two or more studies with comparable exacerbation outcome definitions, using STATA 17.0 (StataCorp, College Station, TX, USA). A random-effects model was used for dichotomous outcomes to calculate relative risk (relative risk) with a 95% confidence interval when more than two studies were combined; alternatively, a fixed-effect model was used. For continuous outcomes, the mean difference was calculated between exacerbation groups. Forest plots were created for each meta-analysis.

Heterogeneity between studies was assessed using the I2 parameter (I2>60% indicates heterogeneity) and Chi-squared test (p<0.1 indicating significant heterogeneity). To investigate heterogeneity, subgroup analysis with random effects by active asthma management was performed for analyses with significant heterogeneity. Publication bias was explored with Egger's tests for analyses including ≥10 studies or more.

Results

35 articles were included in the review (figure 1). In total, 429 583 pregnant women with asthma were included; the proportion of women with an exacerbation during pregnancy ranged from 2.5% [11] to 36.3% [4]. Studies were of good quality (median score 8, interquartile range (IQR) 7–9) (supplementary table S2). All meta-analyses are presented in supplementary table S3, and subgroup analyses in supplementary table S4.

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Flow diagram of included studies.

Maternal factors

Maternal age was reported in nine studies [4, 8, 12, 14, 24–28]. Six studies [4, 12, 24–27] reporting mean±sd were combined in a meta-analysis finding exacerbations associated with higher age (mean difference 0.62 years, 95% CI 0.11–1.13 years; I2=0.0%) (figure 2a). Four studies reported age categories; one study [8] with a cut-off age of 34 years, and three [4, 14, 28] studies with a cut-off age of 35 years. Meta-analysis showed a 27% increased risk of exacerbation with maternal age ≥35 years (relative risk 1.27, 95% CI 1.06–1.52; I2=87.8%). Heterogeneity remained after subgroup analysis.

FIGURE 2
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2

Forest plots of meta-analyses. a) Age, b) obesity and c) smoking status. Exa: exacerbation.

Maternal body mass index (BMI) was reported in nine studies [4, 12, 14, 16, 24–27, 29]. Two studies [4, 27] reported data as median (IQR) with no statistical difference between exacerbation status; three studies [12, 24, 25] were combined in a meta-analysis, showing no association between exacerbation status and BMI (mean difference 1.82 kg·m−2, 95% CI –1.12–4.75 kg·m−2; I2=95.2%). Five studies [12, 14, 16, 26, 27] reported BMI categories; meta-analysis showed a significant 25% increased risk of exacerbation in obese versus nonobese women (relative risk 1.25, 95% CI 1.15–1.37; I2=0.0%) (figure 2b). One study [29] reported decreased odds of exacerbation for women with a nonobese BMI compared to an obese BMI.

Maternal cigarette smoking was reported in 10 studies [4, 8, 12, 14, 25–30], of which nine [4, 8, 12, 14, 25–28, 30] were included in a meta-analysis, showing a 35% increased risk of exacerbation with current smoking versus nonsmoking (relative risk 1.35, 95% CI 1.04–1.75; I2=94.0%) (figure 2c). Heterogeneity remained in the active management subgroup.

Maternal ethnicity was reported in four studies [26, 27, 31, 32], two [26, 31] of which were combined in a meta-analysis, showing an increased risk of exacerbation in American women of black versus white ethnicity (relative risk 1.62, 95% CI 1.52–1.73; I2=94.0%). One study [32] also reported an increased risk of hospitalisation, emergency department visit and OCS use for women of black ethnicity. One Australian study reported no difference in exacerbations between women of white/European, Indigenous and other/unknown ethnicity [27]. One study [14] reported an increased risk of exacerbations among women born outside Europe versus those born within Europe.

Three studies [8, 25, 28] reported on rurality of maternal residence and were combined in a meta-analysis showing no difference in exacerbation risk for rural versus metropolitan/regional residence (relative risk 0.92, 95% CI 0.66–1.28; I2=95.2%). Heterogeneity remained after subgroup analysis.

Single studies found increased risks of exacerbations for women of low social class versus high class [28], women without a partner versus with a partner [28], women with at least three children in the household versus fewer than three children [28], women with ≤12 years versus ≥13 years of education [14] and women who were illiterate versus those with intermediate/high education [25].

One Canadian study [26] reported on insurance type (public or private), showing no difference in exacerbation risk. Greater proportions of women with an exacerbation during pregnancy were in the “most deprived” categories for material deprivation and residential instability quintiles from the Ontario Marginalization Index [8].

Maternal comorbidities were reported in seven studies [14, 25, 26, 28, 29, 33, 34]. Women with anxiety and/or depression were at significantly higher risk of exacerbation compared to women without anxiety and/or depression (relative risk 1.42, 95% CI 1.27–1.59; I2=68.7%) (two studies [14, 33]). One study [27] reported that women with higher risk scores on the Edinburgh Postnatal Depression Scale were at higher risk of exacerbations. Gastro-oesophageal reflux disease and allergic rhinitis were reported in two studies [25, 26] and were not associated with exacerbation risk (relative risk 0.98, 95% CI 0.61–1.58; I2=0.0% and relative risk 1.28, 95% CI 0.85–1.92; I2=89.5%, respectively). Low vitamin D [35], allergy [29] and atopy [25] were each reported in one study and none were associated with exacerbation risk during pregnancy.

Pregnancy factors

Women with exacerbations during pregnancy gained significantly less weight during pregnancy (mean difference −2.71 kg, 95% CI −4.48– −0.94 kg; I2=69.3%) (three studies [4, 12, 24]; figure 3a) compared to women without exacerbations. One study reported no difference in exacerbation risk between women who gained weight above recommendations versus below/within recommendations [15]. Fetal sex was not associated with exacerbation risk based on a meta-analysis of 10 studies [4, 8, 12, 24–28, 36, 37] (relative risk 1.05, 95% CI 0.89–1.25; I2=88.9%; male versus female, no publication bias p=0.91), and in one study by exacerbation type [38]. Heterogeneity remained in the active involvement subgroup. Six studies [4, 12, 14, 24, 27, 28] were included in a meta-analysis comparing showing a 31% increased risk of exacerbation for multiparous women versus nulliparous (relative risk 1.31, 95% CI 1.01–1.68; I2=89.1%) (figure 3b). Heterogeneity remained in the active involvement subgroup. Women carrying twins or triplets were at a more than two-fold increased risk of exacerbation compared to singleton pregnancies (relative risk 2.23, 95% CI 1.10–4.50; I2=68.9%) (three studies [24, 26, 27]; figure 3c). Heterogeneity did not remain in subgroup analysis.

FIGURE 3
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3

Forest plots of meta-analyses. a) Gestational weight gain, b) parity and c) plurality. Exa: exacerbation.

Antenatal model of care (midwife/medical/shared care) was not associated with exacerbations [27].

Asthma factors

Six studies [4, 5, 25, 39–41] containing seven populations were included in meta-analyses showing that women with moderate/severe asthma, based on medication utilisation, were 3.4 times more likely to have an exacerbation compared to women with mild asthma (relative risk 3.44, 95% CI 2.03–5.83; I2=99.2%) (figure 4a). Women with severe asthma were 2.7 times more likely to have an exacerbation compared to moderate/mild asthma (relative risk 2.70, 95% CI 1.85–3.95; I2=98.5%). Heterogeneity remained in subgroup analysis.

FIGURE 4
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 4

Forest plots of meta-analyses. a) Asthma severity, b) history of recent hospitalisation/emergency department visit for asthma and c) inhaled corticosteroid (ICS) use ∼18 weeks’ gestation. Exa: exacerbation; MS: MarketScan (private insurance); MAX: Medicaid Analytic Extract (public insurance).

History of pre-pregnancy exacerbations, including hospitalisation [27, 42] (relative risk 3.75, 95% CI 2.82–4.97; I2=39.0%) (figure 4b), emergency department visits [27, 42] (relative risk 3.80, 95% CI 2.94–4.90; I2=91.6%) (figure 4b), outpatient visits [42], OCS courses [27] and mechanical ventilation [26] were associated with an increased risk of exacerbations during pregnancy. No history of pre-pregnancy exacerbations (hospitalisation/emergency department visits/OCS courses) was associated with reduced risk of exacerbations during pregnancy (OR 0.22, 95% CI 0.14–0.35) [29].

Nine [12, 14, 26, 27, 29, 42–45] studies reported the use of inhaled corticosteroid (ICS). Two studies [12, 27] reported that women using ICS at study enrolment (∼18 weeks’ gestation) were 65% more likely to have an exacerbation later during pregnancy (relative risk 1.65, 95% CI 1.42–1.92; I2=0.0%) (figure 4c). One [29] study reported reduced odds for exacerbation among women without an ICS prescription in early pregnancy compared to those with ICS. One study reported that women using ICS with long-acting β-agonists (LABA) in mid-pregnancy were at increased risk of exacerbation [27]. One study reported no difference in exacerbations per month during pregnancy between treatment groups (no ICS, ICS mono-therapy, ICS/LABA therapy) [45]. Additionally, this study reported higher odds of exacerbation among those treated with ICS/LABA in mid-pregnancy compared to no ICS [45].

Two studies reported on medication dosage; one found significant odds for exacerbation with mid-pregnancy low–moderate doses versus no ICS and for high doses versus no ICS. One RCT reported no difference in risk of exacerbation among women treated with beclomethasone versus theophylline [44]. No difference was found between step-up in ICS dose versus step-down [46]

Four [4, 25, 27, 29] studies reported various spirometry measures. One study [29] reported reduced risk of future exacerbations in women with a forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio above the lower limit of normal (LLN) compared to a ratio below the LLN. In one study [27], decreased FEV1% predicted was associated with an increased risk of future exacerbations treated with OCS, while mean FVC% predicted also differed in women treated with OCS versus no OCS [27]. Other studies reported no differences in lung function by exacerbation status [4, 25, 27, 29].

Lung inflammation measured by fraction of exhaled nitric oxide (FeNO) was not associated with future exacerbations in one study [27], whereas another study reported a reduced risk of exacerbations for those with FeNO levels <25 ppb [29]. There was no difference between asthma subtypes [47].

Higher scores on the Asthma Quality of Life Questionnaire were associated with reduced risk of exacerbation [48], with similar estimates for the emotion and symptom subdomains [49]. Higher scores on the consequences, identity and emotional response domains from the illness perception questionnaire were associated with increased exacerbation risk during pregnancy [49], but no association with Pregnancy Asthma Control Test [50]. The same study [49] reported a reduced risk of exacerbations with lower scores on the Perceived Control of Asthma Questionnaire. Worse asthma control measured using the Asthma Control Questionnaire [27] or Global Initiative for Asthma (GINA) standards [27, 51] was associated with an increased risk of exacerbations. Clinically stable asthma (well controlled by GINA guidelines, FEV1 >80% predicted and FeNO <25 ppb) before 18 weeks’ gestation was associated with a reduced risk of exacerbations during the remainder of pregnancy [29].

Two studies reported antenatal asthma management strategies. A nurse-led programme versus standard care did not have a significant effect on reducing exacerbations [52], while an inflammation-based management versus a symptom-based management significantly reduced exacerbation risk during pregnancy [53].

One study reported higher prevalence of certain self-reported asthma triggers, such as reflux, work environment, pets, foods, aspirin and fumes, among pregnant women who experienced an exacerbation compared to those who did not exacerbate [27].

Asthma self-management skills such as correct medication knowledge and ICS nonadherence at ∼18 weeks’ gestation were not associated with future exacerbations, whereas good inhaler technique and possession of a written action plan were associated with an increased risk of exacerbations in one study [27].

Discussion

Main findings

This is the first systematic review and meta-analysis to synthesise the literature on risk factors for asthma exacerbations during pregnancy. The greatest increased risk of exacerbations requiring medical intervention was a 3.4-fold increased risk for women with moderate to severe asthma, compared to women with mild asthma. Women carrying twins/triplets were at a 2.2-fold risk for an exacerbation compared to women carrying singletons. Furthermore, there was a 62% increased risk for asthma exacerbations in pregnancy for women of black ethnicity, a 42% increased risk for women with depression and anxiety, a 35% increased risk for current smokers, a 31% increased risk for multiparous women, a 27% increased risk for women aged >35 years and a 25% increased risk for obese women.

Strengths and limitations

Although some of the factors presented in this review are already known, this study has several strengths: the systematic approach to reviewing the literature, the inclusion of meta-analyses and the use of GRADE, showing high certainty for many of the analyses. However, there were some limitations, including high heterogeneity between studies. The latter may have been related to the observational nature of the cohort studies reviewed, and the influence of potential confounding factors.

ICS use varies between countries [54] and may be associated with different prevalence of exacerbations. Unfortunately, we were only able to combine two Australian studies on ICS use at 18 weeks’ gestation to give a relative risk of ICS use or dose for asthma exacerbations in pregnancy. Individual studies showed that expectant mothers with lower education and those born outside Europe were at increased risk of having an asthma exacerbation. Further research is needed to determine whether these factors, and black ethnicity, are indicative of health literacy and whether that is the underlying risk factor. Health literacy has been reported to affect long-term asthma outcomes and exacerbations [55]. Others may also have underlying risk factors; indicators such as pre-pregnancy exacerbations, ICS or ICS/LABA use, good inhaler technique and possession of a written action plan may be associated with moderate–severe asthma.

Interpretation

Several of the risk factors for exacerbation identified in this review are also risk factors for adverse perinatal outcomes, in general, and specifically for women with asthma. Cigarette smoking is known to contribute to low birthweight [56] and preterm birth [57], adverse outcomes that are more common among women with asthma [58], and specifically those who exacerbate during pregnancy [9, 59]. Among adults with asthma, smoking reduces response to treatment with corticosteroids [60–62]. Therefore, smoking cessation is recommended for all people with asthma who smoke, as achieving good asthma control is more difficult among smokers. For women of childbearing age smoking cessation prior to pregnancy may improve asthma control, increase responsiveness to treatment and improve perinatal and infant outcomes [56, 57, 63, 64].

We showed previously that maternal overweight and obesity, but not excess gestational weight gain [65], was associated with exacerbations of asthma in pregnancy, and driven by macrophage activation, measured as elevated serum soluble CD163 [15]. Among adults with asthma, obesity reduces response to ICS treatment, limiting asthma control [66]. The results of this review support recommendations to lose weight prior to pregnancy for women with asthma with overweight and obese BMI. Weight loss may reduce exacerbation risk, and the risk of adverse perinatal outcomes [67, 68].

The prevalence of depression and other mental illnesses is common among pregnant women with asthma [33, 69]. Adults with asthma and depression/anxiety have higher rates of other risk factors for asthma exacerbations, such as smoking, obesity and increasing asthma severity, compared to adults with asthma without depression/anxiety [70]. It is unknown whether the biological changes associated with mental illness increase the risk of exacerbation or whether the risk of exacerbations can be mitigated by treatment, both pharmaceutical and nonpharmaceutical.

Healthcare professionals caring for women with asthma who are pregnant or planning a pregnancy could use the risk factors from this review to identify women at particular risk of exacerbation. For women planning a pregnancy, modifiable risk factors such as obesity and smoking should be addressed as early as possible to mitigate the risk of exacerbations. These data support the development of a “treatable traits” approach to asthma management during pregnancy, which in addition to pulmonary traits (such as airway inflammation and symptoms), addresses extrapulmonary traits such as depression/anxiety and behavioural traits such as smoking. In the context of severe asthma, traits such as being prone to exacerbations, depression and vocal cord dysfunction, were associated with future exacerbation risk [71, 72], and a trial of a treatable traits approach improved both asthma control and health-related quality of life [73].

In conclusion, this systematic review and meta-analysis has corroborated an increased asthma exacerbation risk in pregnancy in association with moderate and severe asthma, maternal age, obesity, smoking, black ethnicity, depression and anxiety and parity. Future interventions aimed at reducing exacerbations in pregnancy could address modifiable factors and introduce more regular monitoring for those with nonmodifiable risk factors.

Supplementary material

Supplementary Material

Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.

Search strategy ERR-0039-2022.SUPPLEMENT1

Supplementary tables ERR-0039-2022.SUPPLEMENT2

Footnotes

  • Provenance: Submitted article, peer reviewed.

  • Author contributions: A.L. Robijn: study selection, data extraction, data analysis, interpretation of results, writing of manuscript. M.P. Bokern: protocol development, study selection, data extraction. M.E. Jensen: study conception, development search strategy. D. Barker: protocol development, statistical advisor. K.J. Baines: protocol development. V.E. Murphy: study conception, development search strategy, interpretation of results, manuscript writing. All authors read and approved the final manuscript.

  • Conflict of interest: M.P. Bokern reports support for the present manuscript from Groningen Research Institute of Pharmacy, PharmacoTherapy, Epidemiology and Economics, University of Groningen, Groningen, the Netherlands and Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK. M.P. Bokern reports grants or contracts from GlaxoSmithKline (GSK PhD scholarship at London School of Hygiene and Tropical Medicine), outside the submitted work. V.E. Murphy reports support for the present manuscript from Medical Research Future Fund Investigator Grant (paid to her institution). The remaining authors have nothing to disclose.

  • Support statement: M.E. Jensen is supported by a Peggy Lang Hunter Children's Research Foundation Early Career Fellowship. K.J. Baines is funded by an Australian Lung Foundation COPD Research Fellowship and received funding from NHMRC (APP1104645 and APP1144941), and the John Hunter Charitable Trust. V.E. Murphy received a Career Development Fellowship from the NHMRC (grant no. APP1084816), the Gladys M. Brawn Memorial Career Development Fellowship from the University of Newcastle and the Medical Research Futures Fund Investigator Grant (application ID 1196252). The authors alone are responsible for the content of this manuscript. No funding was received for the study.

  • Received February 22, 2022.
  • Accepted April 7, 2022.
  • Copyright ©The authors 2022
http://creativecommons.org/licenses/by-nc/4.0/

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org

References

  1. ↵
    1. Hansen C,
    2. Joski P,
    3. Freiman H, et al.
    Medication exposure in pregnancy risk evaluation program: the prevalence of asthma medication use during pregnancy. Matern Child Health J 2013; 17: 1611–1621. doi:10.1007/s10995-012-1173-x
    OpenUrlCrossRefPubMed
    1. Rejnö G,
    2. Lundholm C,
    3. Gong T, et al.
    Asthma during pregnancy in a population-based study – pregnancy complications and adverse perinatal outcomes. PLoS One 2014; 9: e104755. doi:10.1371/journal.pone.0104755
    OpenUrlPubMed
  2. ↵
    1. Sawicki E,
    2. Stewart K,
    3. Wong S, et al.
    Management of asthma by pregnant women attending an Australian maternity hospital. Aust NZJ Obstet Gynaecol 2012; 52: 183–188. doi:10.1111/j.1479-828X.2011.01385.x
    OpenUrl
  3. ↵
    1. Murphy VE,
    2. Gibson P,
    3. Talbot PI, et al.
    Severe asthma exacerbations during pregnancy. Obstet Gynecol 2005; 106: 1046–1054. doi:10.1097/01.AOG.0000185281.21716.02
    OpenUrlCrossRefPubMed
  4. ↵
    1. Schatz M,
    2. Dombrowski MP,
    3. Wise R, et al.
    Asthma morbidity during pregnancy can be predicted by severity classification. J Allergy Clin Immunol 2003; 112: 283–288. doi:10.1067/mai.2003.1516
    OpenUrlCrossRefPubMed
  5. ↵
    1. Murphy VE,
    2. Gibson PG,
    3. Smith R, et al.
    Asthma during pregnancy: mechanisms and treatment implications. Eur Respir J 2005; 25: 731–750. doi:10.1183/09031936.05.00085704
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Yland JJ,
    2. Bateman BT,
    3. Huybrechts KF, et al.
    Perinatal outcomes associated with maternal asthma and its severity and control during pregnancy. J Allergy Clin Immunol Pract 2020; 8: 1928–1937. doi:10.1016/j.jaip.2020.01.016
    OpenUrl
  7. ↵
    1. Abdullah K,
    2. Zhu J,
    3. Gershon A, et al.
    Effect of asthma exacerbation during pregnancy in women with asthma: a population-based cohort study. Eur Respir J 2020; 55: 1901335. 10.1183/13993003.01335-2019
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Namazy JA,
    2. Murphy VE,
    3. Powell H, et al.
    Effects of asthma severity, exacerbations and oral corticosteroids on perinatal outcomes. Eur Respir J 2013; 41: 1082–1090. doi:10.1183/09031936.00195111
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Martel MJ,
    2. Rey É,
    3. Beauchesne MF, et al.
    Control and severity of asthma during pregnancy are associated with asthma incidence in offspring: two-stage case-control study. Eur Respir J 2009; 34: 579–587. doi:10.1183/09031936.00074608
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Liu X,
    2. Agerbo E,
    3. Schlünssen V, et al.
    Maternal asthma severity and control during pregnancy and risk of offspring asthma. J Allergy Clin Immunol 2018; 141: 886–892. doi:10.1016/j.jaci.2017.05.016
    OpenUrl
  11. ↵
    1. Grzeskowiak LE,
    2. Smith B,
    3. Roy A, et al.
    Patterns, predictors and outcomes of asthma control and exacerbations during pregnancy: a prospective cohort study. ERJ Open Res 2016; 2: 00054-2015. doi:10.1183/23120541.00054-2015
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Murphy VE,
    2. Clifton VL,
    3. Gibson PG
    . The effect of cigarette smoking on asthma control during exacerbations in pregnant women. Thorax 2010; 65: 739–744. doi:10.1136/thx.2009.124941
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Robijn AL,
    2. Brew BK,
    3. Jensen ME, et al.
    Effect of maternal asthma exacerbations on perinatal outcomes: a population-based study. ERJ Open Res 2020; 6: 00295–02020. doi:10.1183/23120541.00295-2020
    OpenUrl
  14. ↵
    1. Murphy VE,
    2. Jensen ME,
    3. Powell H, et al.
    Influence of maternal body mass index and macrophage activation on asthma exacerbations in pregnancy. J Allergy Clin Immunol Pract 2017; 5: 981–987. doi:10.1016/j.jaip.2017.03.040
    OpenUrl
  15. ↵
    1. Hendler I,
    2. Schatz M,
    3. Momirova V, et al.
    Association of obesity with pulmonary and nonpulmonary complications of pregnancy in asthmatic women. Obstet Gynecol 2006; 108: 77–82. doi:10.1097/01.AOG.0000223180.53113.0f
    OpenUrlCrossRefPubMed
  16. ↵
    1. Williams DA
    . Asthma and pregnancy. Acta Allergol 1967; 22: 311–323. doi:10.1111/j.1398-9995.1967.tb03228.x
    OpenUrl
  17. ↵
    1. Belanger K,
    2. Hellenbrand M,
    3. Holford T, et al.
    Effect of pregnancy on maternal asthma symptoms and medication use. Obstet Gynecol 2010; 115: 559–567. doi:10.1097/AOG.0b013e3181d06945
    OpenUrlCrossRefPubMed
  18. ↵
    1. Page MJ,
    2. McKenzie JE,
    3. Bossuyt PM, et al.
    The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev 2021; 10: 89. doi:10.1186/s13643-021-01626-4
    OpenUrlCrossRefPubMed
  19. ↵
    1. Stroup DF,
    2. Berlin JA,
    3. Morton SC
    , et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008–2012. doi:10.1001/jama.283.15.2008
    OpenUrlCrossRefPubMed
  20. ↵
    1. Wells GA,
    2. Shea B,
    3. O'Connell D, et al.
    The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses. 2009. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp Date last accessed: 17 March 2021.
  21. ↵
    1. Higgins JPT,
    2. Altman DG,
    3. Gøtzsche PC, et al.
    The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928. doi:10.1136/bmj.d5928
    OpenUrlFREE Full Text
  22. ↵
    1. Guyatt GH,
    2. Oxman AD,
    3. Vist GE, et al.
    GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924–926. doi:10.1136/bmj.39489.470347.AD
    OpenUrlFREE Full Text
  23. ↵
    1. Ali Z,
    2. Nilas L,
    3. Ulrik CS
    . Excessive gestational weight gain in first trimester is a risk factor for exacerbation of asthma during pregnancy: a prospective study of 1283 pregnancies. J Allergy Clin Immunol 2018; 141: 761–767. doi:10.1016/j.jaci.2017.03.040
    OpenUrl
  24. ↵
    1. Shebl E,
    2. Abbas A,
    3. Ramadan M
    . Incidence, risk factors, and outcome of bronchial asthma exacerbation in pregnancy: is there a change from prior estimates? Egypt J Chest Dis Tuberc 2019; 68: 536–541.
    OpenUrl
  25. ↵
    1. Yoo EJ,
    2. Lee NL,
    3. Huang KP, et al.
    Clinical characteristics of severe asthma exacerbations among inner-city women in pregnancy. J Allergy Clin Immunol Pract 2020; 8: 395–397. doi:10.1016/j.jaip.2019.06.010
    OpenUrl
  26. ↵
    1. Bokern M,
    2. Robijn A,
    3. Jensen ME, et al.
    Factors associated with asthma exacerbations during pregnancy. J Allergy Clin Immunol Pract 2021; 9: 4343–4352. doi:10.1016/j.jaip.2021.07.055
    OpenUrl
  27. ↵
    1. Liu X,
    2. Dalsgaard S,
    3. Munk-Olsen T, et al.
    Parental asthma occurrence, exacerbations and risk of attention-deficit/hyperactivity disorder. Brain Behav Immun 2019; 82: 302–308. doi:10.1016/j.bbi.2019.08.198
    OpenUrl
  28. ↵
    1. Ali Z,
    2. Nilas L,
    3. Ulrik CS
    . Determinants of low risk of asthma exacerbation during pregnancy. Clin Exp Allergy 2018; 48: 23–28. doi:10.1111/cea.13033
    OpenUrl
  29. ↵
    1. Newman RB,
    2. Momirova V,
    3. Dombrowski MP, et al.
    The effect of active and passive household cigarette smoke exposure on pregnant women with asthma. Chest 2010; 137: 601–608. doi:10.1378/chest.09-0942
    OpenUrlCrossRefPubMed
  30. ↵
    1. Enriquez R,
    2. Griffin MR,
    3. Carroll KN, et al.
    Effect of maternal asthma and asthma control on pregnancy and perinatal outcomes. J Allergy Clin Immunol 2007; 120: 625–630. doi:10.1016/j.jaci.2007.05.044
    OpenUrlCrossRefPubMed
  31. ↵
    1. Carroll KN,
    2. Griffin MR,
    3. Gebretsadik T, et al.
    Racial differences in asthma morbidity during pregnancy. Obstet Gynecol 2005; 106: 66–72. doi:10.1097/01.AOG.0000164471.87157.4c
    OpenUrlPubMed
  32. ↵
    1. Grzeskowiak LE,
    2. Smith B,
    3. Roy A, et al.
    Impact of a history of maternal depression and anxiety on asthma control during pregnancy. J Asthma 2017; 54: 706–713. doi:10.1080/02770903.2016.1258080
    OpenUrl
  33. ↵
    1. Jensen ME,
    2. Camargo CA,
    3. Harvey SM, et al.
    Serum 25 hydroxyvitamin D levels during pregnancy in women with asthma: associations with maternal characteristics and adverse maternal and neonatal outcomes. Nutrients 2020; 12: 2978. doi:10.3390/nu12102978
    OpenUrl
  34. ↵
    1. Jensen ME,
    2. Murphy VE,
    3. Gibson PG, et al.
    Vitamin D status in pregnant women with asthma and its association with adverse respiratory outcomes during infancy. J Matern Fetal Neonatal Med 2019; 32: 1820–1825. doi:10.1080/14767058.2017.1419176
    OpenUrl
  35. ↵
    1. Firoozi F,
    2. Ducharme FM,
    3. Lemière C, et al.
    Effect of fetal gender on maternal asthma exacerbations in pregnant asthmatic women. Respir Med 2009; 103: 144–151. doi:10.1016/j.rmed.2008.07.013
    OpenUrlCrossRefPubMed
  36. ↵
    1. Bakhireva LN,
    2. Schatz M,
    3. Jones KL, et al.
    Asthma control during pregnancy and the risk of preterm delivery or impaired fetal growth. Ann Allergy Asthma Immunol 2008; 101: 137–143. doi:10.1016/S1081-1206(10)60201-3
    OpenUrlCrossRefPubMed
  37. ↵
    1. Bakhireva LN,
    2. Schatz M,
    3. Jones KL, et al
    . Fetal sex and maternal asthma control in pregnancy. J Asthma 2008; 45: 403–407. http://dx.doi.org/10.1080/02770900801971826.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Charlton RA,
    2. Hutchison A,
    3. Davis KJ, et al.
    Asthma management in pregnancy. PLoS One 2013; 8: e60247. doi:10.1371/journal.pone.0060247
    OpenUrlCrossRefPubMed
    1. Cohen JM,
    2. Bateman BT,
    3. Huybrechts KF, et al.
    Poorly controlled asthma during pregnancy remains common in the United States. J Allergy Clin Immunol Pract 2019; 7: 2672–2680. doi:10.1016/j.jaip.2019.05.043
    OpenUrl
  39. ↵
    1. Tanacan A,
    2. Fadiloglu E,
    3. Celebioglu ED, et al.
    The effect of asthma severity on perinatal outcomes: a tertiary hospital experience. Z Geburtshilfe Neonatol 2021; 225: 333–340. doi:10.1055/a-1264-8207
    OpenUrl
  40. ↵
    1. Kim S,
    2. Kim J,
    3. Park SY, et al.
    Effect of pregnancy in asthma on health care use and perinatal outcomes. J Allergy Clin Immunol 2015; 136: 1215–1223. doi:10.1016/j.jaci.2015.04.043
    OpenUrl
    1. Blais L,
    2. Firoozi F,
    3. Kettani F-ZZ, et al.
    Relationship between changes in inhaled corticosteroid use and markers of uncontrolled asthma during pregnancy. Pharmacotherapy 2012; 32: 202–209. doi:10.1002/j.1875-9114.2012.01091.x
    OpenUrlCrossRefPubMed
  41. ↵
    1. Dombrowski MP,
    2. Schatz M,
    3. Wise R, et al.
    Randomized trial of inhaled beclomethasone dipropionate versus theophylline for moderate asthma during pregnancy. Am J Obstet Gynecol 2004; 190: 737–744. doi:10.1016/j.ajog.2003.09.071
    OpenUrlCrossRefPubMed
  42. ↵
    1. Rohn MCH,
    2. Stevens DR,
    3. Kanner J, et al.
    Asthma medication regimens in pregnancy: longitudinal changes in asthma status. Am J Perinatol 2021; in press [https://doi.org/10.1055/s-0041-1727233].
  43. ↵
    1. Murphy VE,
    2. Jensen ME,
    3. Gibson PG
    . Exacerbations of asthma following step-up and step-down inhaled corticosteroid and long acting beta agonist therapy in the Managing Asthma in Pregnancy study. J Asthma 2022; 59: 362–369. http://dx.doi.org/10.1080/02770903.2020.1847934.
    OpenUrl
  44. ↵
    1. Murphy VE,
    2. Porsbjerg CM,
    3. Robijn AL, et al
    . Biomarker-guided management reduces exacerbations in non-eosinophilic asthma in pregnancy: a secondary analysis of a randomized controlled trial. Respirology 2020; 25: 719–725. http://dx.doi.org/10.1111/resp.13713.
    OpenUrl
  45. ↵
    1. Schatz M,
    2. Dombrowski MP,
    3. Wise R, et al
    . The relationship of asthma-specific quality of life during pregnancy to subsequent asthma and perinatal morbidity. J Asthma 2010; 47: 46–50. http://dx.doi.org/10.3109/02770900903483758
    OpenUrlCrossRefPubMed
  46. ↵
    1. Powell H,
    2. McCaffery K,
    3. Murphy VE, et al.
    Psychosocial variables are related to future exacerbation risk and perinatal outcomes in pregnant women with asthma. J Asthma 2013; 50: 383–389. doi:10.3109/02770903.2012.757777
    OpenUrlCrossRefPubMed
  47. ↵
    1. Palmsten K,
    2. Schatz M,
    3. Chan PH, et al
    . Validation of the pregnancy asthma control test. J Allergy Clin Immunol Pract 2016; 4: 310–315. http://dx.doi.org/10.1016/j.jaip.2015.11.019.
    OpenUrl
  48. ↵
    Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2019. Available from: http://ginasthma.org/.
  49. ↵
    1. Grzeskowiak LE,
    2. Smith B,
    3. Roy A, et al.
    An observational study of the impact of an antenatal asthma management service on asthma control during pregnancy. Eur J Obstet Gynecol Reprod Biol 2016; 197: 48–53. doi:10.1016/j.ejogrb.2015.11.038
    OpenUrl
  50. ↵
    1. Powell H,
    2. Murphy VE,
    3. Taylor DR, et al.
    Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet 2011; 378: 983–990. doi:10.1016/S0140-6736(11)60971-9
    OpenUrlCrossRefPubMed
  51. ↵
    1. Robijn AL,
    2. Jensen ME,
    3. McLaughlin K, et al.
    Inhaled corticosteroid use during pregnancy among women with asthma: a systematic review and meta-analysis. Clin Exp Allergy 2019; 49: 1403–1417. doi:10.1111/cea.13474
    OpenUrl
  52. ↵
    1. Mancuso CA,
    2. Rincon M
    . Impact of health literacy on longitudinal asthma outcomes. J Gen Intern Med 2006; 21: 813–817. doi:10.1111/j.1525-1497.2006.00528.x
    OpenUrlCrossRefPubMed
  53. ↵
    1. Rumrich I,
    2. Vähäkangas K,
    3. Viluksela M, et al.
    Effects of maternal smoking on body size and proportions at birth: a register-­based cohort study of 1.4 million births. BMJ Open 2020; 10: e033465. doi:10.1136/bmjopen-2019-033465
    OpenUrlAbstract/FREE Full Text
  54. ↵
    1. Soneji S,
    2. Beltrán-Sánchez H
    . Association of maternal cigarette smoking and smoking cessation with preterm birth. JAMA Netw Open 2019; 2: e192514. doi:10.1001/jamanetworkopen.2019.2514
    OpenUrl
  55. ↵
    1. Murphy V,
    2. Namazy J,
    3. Powell H, et al.
    A meta-analysis of adverse perinatal outcomes in women with asthma. BJOG 2011; 118: 1314–1323. doi:10.1111/j.1471-0528.2011.03055.x
    OpenUrlCrossRefPubMed
  56. ↵
    1. Murphy VE,
    2. Wang G,
    3. Namazy JA, et al.
    The risk of congenital malformations, perinatal mortality and neonatal hospitalisation among pregnant women with asthma: a systematic review and meta-analysis. BJOG 2013; 120: 813–822.
    OpenUrl
  57. ↵
    1. Tomlinson JEM,
    2. McMahon AD,
    3. Chaudhuri R, et al.
    Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax 2005; 60: 282–287. doi:10.1136/thx.2004.033688
    OpenUrlAbstract/FREE Full Text
    1. Lazarus SC,
    2. Chinchilli VM,
    3. Rollings NJ, et al.
    Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med 2007; 175: 783–790. doi:10.1164/rccm.200511-1746OC
    OpenUrlCrossRefPubMed
  58. ↵
    1. Chaudhuri R,
    2. Livingston E,
    3. McMahon AD, et al.
    Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med 2003; 168: 1308–1311. doi:10.1164/rccm.200304-503OC
    OpenUrlCrossRefPubMed
  59. ↵
    1. Brand JS,
    2. Gaillard R,
    3. West J, et al.
    Associations of maternal quitting, reducing, and continuing smoking during pregnancy with longitudinal fetal growth: findings from Mendelian randomization and parental negative control studies. PLoS Med 2019; 16: e1002972. doi:10.1371/journal.pmed.1002972
    OpenUrlCrossRefPubMed
  60. ↵
    1. De Queiroz Andrade E,
    2. Da Silva Sena CR,
    3. Collison A, et al.
    Association between active tobacco use during pregnancy and infant respiratory health: a systematic review and meta-analysis. BMJ Open 2020; 10: e037819. doi:10.1136/bmjopen-2020-037819
    OpenUrlAbstract/FREE Full Text
  61. ↵
    1. Murphy VE,
    2. Jensen ME,
    3. Robijn AL, et al
    . How maternal BMI modifies the impact of personalized asthma management in pregnancy. J Allergy Clin Immunol Pract 2020; 8: 219–228.e3. http://dx.doi.org/10.1016/j.jaip.2019.06.033.
    OpenUrl
  62. ↵
    1. Baffi CW,
    2. Winnica DE,
    3. Holguin F
    . Asthma and obesity: mechanisms and clinical implications. Asthma Res Pract 2015; 1: 1. doi:10.1186/s40733-015-0001-7
    OpenUrlPubMed
  63. ↵
    1. Nagpal TS,
    2. Souza SCS,
    3. Moffat M, et al.
    Does prepregnancy weight change have an effect on subsequent pregnancy health outcomes? A systematic review and meta-analysis. Obes Rev 2022; 23: e13324. doi:10.1111/obr.13324
    OpenUrlPubMed
  64. ↵
    1. Juel CT,
    2. Ali Z,
    3. Nilas L, et al.
    Asthma and obesity: does weight loss improve asthma control? A systematic review. J Asthma Allergy 2012; 5: 21–26. doi:10.2147/JAA.S32232
    OpenUrlCrossRefPubMed
  65. ↵
    1. Whalen OM,
    2. Campbell LE,
    3. Murphy VE, et al.
    Observational study of mental health in asthmatic women during the prenatal and postnatal periods. J Asthma 2020; 57: 829–841. doi:10.1080/02770903.2019.1621888
    OpenUrl
  66. ↵
    1. Trzcinska H,
    2. Zwierzchowska B,
    3. Kozlowski B, et al.
    Analysis of the role of selected demographic and psychological variables (anxiety and depression) as risk factors of inadequate control of bronchial asthma. Ann Agric Environ Med 2013; 20: 504–508.
    OpenUrl
  67. ↵
    1. McDonald VM,
    2. Hiles SA,
    3. Godbout K, et al.
    Treatable traits can be identified in a severe asthma registry and predict future exacerbations. Respirology 2019; 24: 37–47. doi:10.1111/resp.13389
    OpenUrl
  68. ↵
    1. Hiles SA,
    2. Gibson PG,
    3. Agusti A, et al.
    Treatable traits that predict health status and treatment response in airway disease. J Allergy Clin Immunol Pract 2021; 9: 1255–1264. doi:10.1016/j.jaip.2020.09.046
    OpenUrl
  69. ↵
    1. McDonald VM,
    2. Clark VL,
    3. Cordova-Rivera L, et al.
    Targeting treatable traits in severe asthma: a randomised controlled trial. Eur Respir J 2020; 55: 1901509. doi:10.1183/13993003.01509-2019
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
View this article with LENS
Vol 31 Issue 164 Table of Contents
European Respiratory Review: 31 (164)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Risk factors for asthma exacerbations during pregnancy: a systematic review and meta-analysis
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Risk factors for asthma exacerbations during pregnancy: a systematic review and meta-analysis
Annelies L. Robijn, Marleen P. Bokern, Megan E. Jensen, Daniel Barker, Katherine J. Baines, Vanessa E. Murphy
European Respiratory Review Jun 2022, 31 (164) 220039; DOI: 10.1183/16000617.0039-2022

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Risk factors for asthma exacerbations during pregnancy: a systematic review and meta-analysis
Annelies L. Robijn, Marleen P. Bokern, Megan E. Jensen, Daniel Barker, Katherine J. Baines, Vanessa E. Murphy
European Respiratory Review Jun 2022, 31 (164) 220039; DOI: 10.1183/16000617.0039-2022
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Supplementary material
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Asthma and allergy
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Pathogenesis of tuberculosis: the 1930 Lübeck disaster revisited
  • Predictors of sleep disordered breathing in children with Down syndrome
Show more Reviews

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERR

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising
  • Sponsorship

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 0905-9180
Online ISSN: 1600-0617

Copyright © 2022 by the European Respiratory Society